Goldman Sachs is in the spotlight as tech firms Arm and Instacart test IPO market | Moderna says mRNA flu shot generates better immune response in study than currently available vaccine | CNN | Location of Ramaswamy Speech Speaks Volumes About GOP Race

View online | Unsubscribe (one-click). For inquiries/unsubscribe issues, Contact Us

You Might Like � � � � � � � � � Don't like ads? Go ad-free with TradeBriefs Premium Goldman Sachs is in the spotlight as tech firms Arm and Instacart test IPO market - CNBC    The return of large tech IPOs this week after a prolonged drought isn't just a test of investors' appetite for risky new offerings — it's a key moment for Wall Street's top advisor, Goldman Sachs. Chip designer Arm is expected to begin trading Thursday in the year's biggest listing. Delivery firm Instacart and marketing automation platform Klaviyo are expected to list as soon as next week. While they each operate in vastly different parts of the tech universe, the companies have one important thing in common: Goldman is a key advisor. Continued here You Might Like � � � � � � � � � Moderna says mRNA flu shot generates better immune response in study than currently available vaccine | CNN - CNN    Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 study, paving the way for the company to discuss a path to approval with regulators. The experimental shot, dubbed mRNA-1010, was compared with a currently approved seasonal flu vaccine from GSK called Fluarix. The results are from an interim analysis and were disclosed in a company news release Wednesday morning. In hopeful sign for the US, flu vaccine shows strong protection against hospitalization in South America, CDC report shows Continued here You Might Like � � � � � � � � � Location of Ramaswamy Speech Speaks Volumes About GOP Race - Time    Later this morning, Vikek Ramaswamy will stride into the lobby of a seven-story building on the boulevard between the Capitol and the White House to deliver what his campaign advisers call a major policy speech. The biotech investor intends to get in specifics of how exactly he plans to exploit the full powers of a unitary and nearly unlimited executive branch in ways that Donald Trump fell short of doing. This is not surprising policy fare, coming from a presidential candidate. What is more notable is the location. Rather than traveling to an early primary state to spell out how he plans to scrap a huge portion of the federal workforce without consulting Congress, Ramaswamy is rolling out his framework at the offices of a think tank widely seen as largely existing to serve as a White House-in-waiting for his chief rival. That’s right. Ramaswamy is speaking at the Trump-aligned America First Policy Institute, a nonprofit helmed by his loyalists and headquartered kitty-corner to his former flagship D.C. hotel. Officially independent of the Trump campaign and nominally nonpartisan, it nonetheless draws funding from his super PAC (along with anonymous megadonors) and counts former top Trump aides like Linda McMahon and Larry Kudlow as leaders. But much like The Center for American Progress was seen as ClintonLand in Exile, America First is Trump’s hot plate for the smarties who might, in the next term, finish the unfinished job. This one is, to its credit, doing some legitimate scholarship.  Continued here

You Might Like � � �

�

�

�

�

�

�

You are receiving this mailer as a TradeBriefs subscriber. We fight fake/biased news through human curation & independent editorials. Your support of ads like these makes it possible. Alternatively, get TradeBriefs Premium (ad-free) for only $2/month If you still wish to unsubscribe, you can unsubscribe from all our emails here Our address is 309 Town Center 1, Andheri Kurla Road, Andheri East, Mumbai 400059 - 437931932